{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:06:28Z","timestamp":1761674788053},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2002,3,1]]},"DOI":"10.1038\/sj.cgt.7700439","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:20:35Z","timestamp":1031250035000},"page":"282-288","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Cendrine","family":"Grangeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Cormary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vickorine","family":"Douin-Echinard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Favre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Couderc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Fran\u00e7oise","family":"Tilkin-Mariam\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,3,12]]},"reference":[{"key":"BF7700439_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0952-7915(97)80050-7","volume":"9","author":"BJ Van den Eynde","year":"1997","unstructured":"Van den Eynde BJ, van der Bruggen P . T cell defined tumor antigens Curr Opin Immunol 1997 9: 684","journal-title":"Curr Opin Immunol"},{"key":"BF7700439_CR2","first-page":"163","volume":"5","author":"B Couderc","year":"1998","unstructured":"Couderc B, Zitvogel L, Douin-Echinard V et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells Cancer Gene Ther 1998 5: 163","journal-title":"Cancer Gene Ther"},{"key":"BF7700439_CR3","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.4049\/jimmunol.156.9.3382","volume":"156","author":"IR Williams","year":"1996","unstructured":"Williams IR, Ort RJ, Daley D et al. Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas J Immunol 1996 156: 3382","journal-title":"J Immunol"},{"key":"BF7700439_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-4615-5357-1_55","volume":"451","author":"V Douin-Echinard","year":"1998","unstructured":"Douin-Echinard V, Robbins PD, Lotze MT, Favre G, Couderc B . Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70 Adv Exp Med Biol 1998 451: 353","journal-title":"Adv Exp Med Biol"},{"key":"BF7700439_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00002371-199805000-00009","volume":"21","author":"JD Nieland","year":"1998","unstructured":"Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM . CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response J Immunother 1998 21: 225","journal-title":"J Immunother"},{"key":"BF7700439_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1006\/smim.1998.0147","volume":"10","author":"REM Toes","year":"1998","unstructured":"Toes REM, Schoenberger SP, van der Voort EIH, Offringa R, Melief CJM . CD40\u2013CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity Semin Immunol 1998 10: 443","journal-title":"Semin Immunol"},{"key":"BF7700439_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1084\/jem.191.11.2011","volume":"191","author":"AM Moodycliffe","year":"2000","unstructured":"Moodycliffe AM, Shreedhar V, Ullrich SE et al. CD40\u2013CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes J Exp Med 2000 191: 2011","journal-title":"J Exp Med"},{"key":"BF7700439_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1084\/jem.192.1.145","volume":"192","author":"DH Schuurhuis","year":"2000","unstructured":"Schuurhuis DH, Laban S, Toes RE et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell\u2013independent or \u2013dependent stimuli J Exp Med 2000 192: 145","journal-title":"J Exp Med"},{"key":"BF7700439_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0955-3886(97)00022-2","volume":"18","author":"J Banchereau","year":"1997","unstructured":"Banchereau J . Dendritic cells: therapeutic potentials Transfus Sci 1997 18: 313","journal-title":"Transfus Sci"},{"key":"BF7700439_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ . T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions [see comments] Nature 1998 393: 480","journal-title":"Nature"},{"key":"BF7700439_CR11","first-page":"3340","volume":"59","author":"AA Eggert","year":"1999","unstructured":"Eggert AA, Schreurs MW, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration Cancer Res 1999 59: 3340","journal-title":"Cancer Res"},{"key":"BF7700439_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1084\/jem.183.1.87","volume":"183","author":"L Zitvogel","year":"1996","unstructured":"Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide\u2013pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1\u2013associated cytokines [see comments] J Exp Med 1996 183: 87","journal-title":"J Exp Med"},{"key":"BF7700439_CR13","first-page":"1331","volume":"5","author":"MA Morse","year":"1999","unstructured":"Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)\u2013pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen Clin Cancer Res 1999 5: 1331","journal-title":"Clin Cancer Res"},{"key":"BF7700439_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate\u2013pulsed dendritic cells [see comments] Nat Med 1998 4: 328","journal-title":"Nat Med"},{"key":"BF7700439_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s002620050565","volume":"48","author":"U Grohmann","year":"1999","unstructured":"Grohmann U, Belladonna ML, Bianchi R et al. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide\/MHC class II complex Cancer Immunol Immunother 1999 48: 195","journal-title":"Cancer Immunol Immunother"},{"key":"BF7700439_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/73193","volume":"6","author":"A Kugler","year":"2000","unstructured":"Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell\u2013dendritic cell hybrids [see comments] Nat Med 2000 6: 332","journal-title":"Nat Med"},{"key":"BF7700439_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.cgt.7700268","volume":"7","author":"V Douin-Echinard","year":"2000","unstructured":"Douin-Echinard V, Bornes S, Rochaix P et al. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status Cancer Gene Ther 2000 7: 1543","journal-title":"Cancer Gene Ther"},{"key":"BF7700439_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4049\/jimmunol.164.12.6633","volume":"164","author":"P Terheyden","year":"2000","unstructured":"Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC . CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4 + IFN-gamma\u2013producing T cells from tumor-infiltrating lymphocytes J Immunol 2000 164: 663","journal-title":"J Immunol"},{"key":"BF7700439_CR19","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.4049\/jimmunol.140.9.3073","volume":"140","author":"P Giacomini","year":"1988","unstructured":"Giacomini P, Tecce R, Gambari R, Sacchi A, Fisher PB, Natali PG . Recombinant human IFN-gamma but not IFN-alpha or IFN-beta, enhances MHC\u2013 and non-MHC\u2013encoded glycoproteins by a protein synthesis\u2013dependent mechanism J Immunol 1988 140: 3073","journal-title":"J Immunol"},{"key":"BF7700439_CR20","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1084\/jem.191.10.1699","volume":"191","author":"C Klein","year":"2000","unstructured":"Klein C, Bueler H, Mulligan RC . Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines J Exp Med 2000 191: 1699","journal-title":"J Exp Med"},{"key":"BF7700439_CR21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V96.1.91","volume":"96","author":"T Kikuchi","year":"2000","unstructured":"Kikuchi T, Moore MA, Crystal RG . Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors Blood 2000 96: 91","journal-title":"Blood"},{"key":"BF7700439_CR22","first-page":"1107","volume":"61","author":"Y Guilloux","year":"2001","unstructured":"Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y . Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells Cancer Res 2001 61: 1107","journal-title":"Cancer Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/7700439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700439","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:21:02Z","timestamp":1682029262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/7700439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["BF7700439"],"URL":"https:\/\/doi.org\/10.1038\/sj.cgt.7700439","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]},"assertion":[{"value":"10 December 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2002","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}